200 related articles for article (PubMed ID: 33477028)
1. Globotriaosylceramide-related biomarkers of fabry disease identified in plasma by high-performance thin-layer chromatography - densitometry- mass spectrometry.
Jarne C; Membrado L; Savirón M; Vela J; Orduna J; Garriga R; Galbán J; Cebolla VL
J Chromatogr A; 2021 Feb; 1638():461895. PubMed ID: 33477028
[TBL] [Abstract][Full Text] [Related]
2. High-Risk Screening of Fabry Disease: Analysis of Fifteen Urinary Methylated and Non-Methylated Gb
Abaoui M; Boutin M; Lavoie P; Auray-Blais C
Curr Protoc Hum Genet; 2016 Oct; 91():17.24.1-17.24.11. PubMed ID: 27727434
[TBL] [Abstract][Full Text] [Related]
3. Tandem mass spectrometry multiplex analysis of methylated and non-methylated urinary Gb3 isoforms in Fabry disease patients.
Abaoui M; Boutin M; Lavoie P; Auray-Blais C
Clin Chim Acta; 2016 Jan; 452():191-8. PubMed ID: 26593248
[TBL] [Abstract][Full Text] [Related]
4. Analysis of globotriaosylceramide (Gb
Toupin A; Lavoie P; Arthus MF; Abaoui M; Boutin M; Fortier C; Ménard C; Bichet DG; Auray-Blais C
Anal Chim Acta; 2018 Jul; 1015():35-49. PubMed ID: 29530250
[TBL] [Abstract][Full Text] [Related]
5. Profiles of Globotriaosylsphingosine Analogs and Globotriaosylceramide Isoforms Accumulated in Body Fluids from Various Phenotypic Fabry Patients.
Shiga T; Tsukimura T; Kubota T; Togawa T; Sakuraba H
Intern Med; 2024 Jun; 63(11):1531-1537. PubMed ID: 37866916
[TBL] [Abstract][Full Text] [Related]
6. A metabolomic study to identify new globotriaosylceramide-related biomarkers in the plasma of Fabry disease patients.
Manwaring V; Boutin M; Auray-Blais C
Anal Chem; 2013 Oct; 85(19):9039-48. PubMed ID: 23968398
[TBL] [Abstract][Full Text] [Related]
7. Determination of globotriaosylceramide in plasma and urine by mass spectrometry.
Krüger R; Bruns K; Grünhage S; Rossmann H; Reinke J; Beck M; Lackner KJ
Clin Chem Lab Med; 2010 Feb; 48(2):189-98. PubMed ID: 19958207
[TBL] [Abstract][Full Text] [Related]
8. Tandem Mass Spectrometry Quantitation of Lyso-Gb3 and Six Related Analogs in Plasma for Fabry Disease Patients.
Boutin M; Lavoie P; Abaoui M; Auray-Blais C
Curr Protoc Hum Genet; 2016 Jul; 90():17.23.1-17.23.9. PubMed ID: 27367163
[TBL] [Abstract][Full Text] [Related]
9. A Rapid and Simple UHPLC-MS/MS Method for Quantification of Plasma Globotriaosylsphingosine (lyso-Gb3).
Perrone A; Mohamed S; Donadio V; Liguori R; Contin M
Molecules; 2021 Dec; 26(23):. PubMed ID: 34885938
[TBL] [Abstract][Full Text] [Related]
10. Quantification of the Fabry marker lysoGb3 in human plasma by tandem mass spectrometry.
Krüger R; Tholey A; Jakoby T; Vogelsberger R; Mönnikes R; Rossmann H; Beck M; Lackner KJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Feb; 883-884():128-35. PubMed ID: 22138589
[TBL] [Abstract][Full Text] [Related]
11. Determination of globotriaosylceramide analogs in the organs of a mouse model of Fabry disease.
Ishii S; Taguchi A; Okino N; Ito M; Maruyama H
J Biol Chem; 2020 Apr; 295(17):5577-5587. PubMed ID: 32179651
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of lyso-globotriaosylsphingosine in dried blood spots in the differential diagnosis between multiple sclerosis and Anderson-Fabry's disease.
Olivera S; Iñiguez C; García-Fernández L; Sierra JL; Camón AM; Menao S; Torralba MÁ
Mult Scler Relat Disord; 2020 Feb; 38():101466. PubMed ID: 31715500
[TBL] [Abstract][Full Text] [Related]
13. Fabry Disease Biomarkers: Analysis of Urinary Lyso-Gb3 and Seven Related Analogs Using Tandem Mass Spectrometry.
Lavoie P; Boutin M; Abaoui M; Auray-Blais C
Curr Protoc Hum Genet; 2016 Jul; 90():17.22.1-17.22.12. PubMed ID: 27367162
[TBL] [Abstract][Full Text] [Related]
14. Global glycosphingolipid analysis in urine and plasma of female Fabry disease patients.
Heywood WE; Doykov I; Spiewak J; Hallqvist J; Mills K; Nowak A
Biochim Biophys Acta Mol Basis Dis; 2019 Oct; 1865(10):2726-2735. PubMed ID: 31319156
[TBL] [Abstract][Full Text] [Related]
15. Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease.
Sueoka H; Aoki M; Tsukimura T; Togawa T; Sakuraba H
PLoS One; 2015; 10(12):e0144958. PubMed ID: 26661087
[TBL] [Abstract][Full Text] [Related]
16. High-Performance Thin-Layer Chromatography Coupled with Electrospray Ionization Tandem Mass Spectrometry for Identifying Neutral Lipids and Sphingolipids in Complex Samples.
Jarne C; Savirón M; Lapieza MP; Membrado L; Orduna J; Galbán J; Garriga R; Morlock GE; Cebolla VL
J AOAC Int; 2018 Nov; 101(6):1993-2000. PubMed ID: 29571302
[TBL] [Abstract][Full Text] [Related]
17. Normal phase liquid chromatography coupled to quadrupole time of flight atmospheric pressure chemical ionization mass spectrometry for separation, detection and mass spectrometric profiling of neutral sphingolipids and cholesterol.
Farwanah H; Wirtz J; Kolter T; Raith K; Neubert RH; Sandhoff K
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Oct; 877(27):2976-82. PubMed ID: 19646933
[TBL] [Abstract][Full Text] [Related]
18. Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry.
Auray-Blais C; Blais CM; Ramaswami U; Boutin M; Germain DP; Dyack S; Bodamer O; Pintos-Morell G; Clarke JT; Bichet DG; Warnock DG; Echevarria L; West ML; Lavoie P
Clin Chim Acta; 2015 Jan; 438():195-204. PubMed ID: 25149322
[TBL] [Abstract][Full Text] [Related]
19. Densitometry and indirect normal-phase HPTLC-ESI-MS for separation and quantitation of drugs and their glucuronide metabolites from plasma.
Bhatt NM; Chavada VD; Sanyal M; Shrivastav PS
Biomed Chromatogr; 2019 Oct; 33(10):e4602. PubMed ID: 31116448
[TBL] [Abstract][Full Text] [Related]
20. Multiplex tandem mass spectrometry analysis of novel plasma lyso-Gb₃-related analogues in Fabry disease.
Boutin M; Auray-Blais C
Anal Chem; 2014 Apr; 86(7):3476-83. PubMed ID: 24634980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
